What the leadership shake up and guidance update mean for Perrigo stock

Perrigo (PRGO) just combined a sudden leadership change with a reaffirmed 2026 earnings outlook, after CEO and President Patrick Lockwood-Taylor resigned over personal conduct issues unrelated to the company’s business or financials.

The Board has moved quickly by naming existing director Albert A. Manzone as Interim CEO and President and launching a search for a permanent successor. This signals an effort to keep the business on its existing course.

Perrigo’s recent executive change and reaffirmed 2026 earnings outlook come after a mixed price picture, with the 90 day share price return of 13.07% contrasting with a year to date decline of 20.88% and a 1 year total shareholder return decline of 55.24%. This suggests that recent momentum is improving, but long term holders have seen heavy value erosion.

If this kind of leadership reset has you reassessing your watchlist, it can help to broaden the field and scan 20 top founder-led companies

With the stock down 55.24% over the past year, yet trading at a 72.56% intrinsic discount and around a 50% gap to analyst targets, is Perrigo quietly offering value, or is the market already discounting weaker future growth?

Most Popular Narrative: 33.4% Undervalued

Against a last close of $10.99, the most followed narrative pegs Perrigo’s fair value at $16.50, framing a sizeable valuation gap to interrogate.

Increasing consumer cost-consciousness is driving stronger adoption of store-brand (private label) OTC products, with Perrigo reporting accelerated unit and volume share gains; this structural shift is expanding Perrigo's addressable market and supports enduring top-line revenue growth.

Want to see what sits behind that valuation gap? The narrative leans on steadier revenues, rising margins and a future earnings multiple usually reserved for faster growing companies. This raises the question of how those moving parts combine into a single fair value line.

Result: Fair Value of $16.50 (UNDERVALUED)

However, this hinges on infant nutrition and OTC execution. Softer category demand and intense price competition could quickly erode the upside case.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of leadership questions and valuation upside feels finely balanced, do not wait around for consensus. Instead, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop at a single stock when you can quickly scan a wider field of opportunities tailored to different goals and risk levels.

• Target potential mispriced opportunities by reviewing 44 high quality undervalued stocks that combine quality fundamentals with room for a market rerating.
• Strengthen your income stream by checking out 8 dividend fortresses built around higher yield payouts with a focus on resilience.
• Dial down portfolio stress by assessing 71 resilient stocks with low risk scores that score well on financial stability and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.